RecruitingNCT07200375

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

Evaluating Effectiveness and Safety of Glofitamab Based Second-Line Therapy in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Observational, Multicenter, Cohort Study

Sponsor

Hoffmann-La Roche

Enrollment

300 participants

Start Date

Sep 29, 2025

Study Type

OBSERVATIONAL

Conditions

Diffuse Large B Cell Lymphoma

Summary

This study will investigate how well glofitamab-based therapy works and how safe it is in Chinese adult participants with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This observational study is tracking real-world outcomes for Chinese patients with relapsed or treatment-resistant diffuse large B-cell lymphoma (a type of blood cancer) who are receiving a drug called glofitamab. The goal is to understand how well this drug works and how safe it is in everyday clinical practice outside of a controlled trial. **You may be eligible if...** - You have confirmed diffuse large B-cell lymphoma that came back or did not respond after one prior treatment - You are being treated with or plan to start a glofitamab-based regimen (or started it within the past 3 months) **You may NOT be eligible if...** - You are currently participating in or plan to join another interventional clinical trial Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGGlofitamab

Participants will receive glofitamab as part of a cancer-treatment regimen in a real-world setting. No intervention will be administered by study investigators.

Locations(17)

Cancer Hospital Chinese Academy of Medical Sciences.

Langfang, Hebei, China

Chinese Academy of Medical Sciences Hematology Hospital;Lymphoma Diagnosis and Treatment Center

Tianjin, Tianjin Municipality, China

Peking University People's Hospital

Beijing, China

Peking University Third Hospital

Beijing, China

The First Bethune Hospital of Jilin University

Changchun, China

West China Hospital of Sichuan University

Chengdu, China

Guangdong Provincial People's Hospital

Guangzhou, China

Harbin Medical University Cancer Hospital

Harbin, China

Shandong Cancer Hospital

Jinan, China

Ruijin Hospital, Shanghai Jiaotong University School of Medicine

Shanghai, China

Tianjin Cancer Hospital

Tianjin, China

The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, China

Xiehe Hospital, Tongji Medical College Huazhong University of Science & Technology

Wuhan, China

Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology

Wuhan, China

The First Affiliated Hospital of Xian Jiao Tong University

Xi'an, China

Yantai Yu Huangding Hospital

Yantai, China

Henan Cancer Hospital

Zhengzhou, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07200375

Related Trials

A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma

NCT0459464227 locations

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT047398131 location

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

NCT040029471 location

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

NCT05139017121 locations

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients

NCT0484486652 locations